🇺🇸·20h agoIndustry
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Publisher
A
AbbVie News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- AbbVie News
- Region
- USA
- Scope
- Industry
- Published
- July 7, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.abbvie.com
Leave the platform to read the original full article on the publisher site.
Source: AbbVie News
Scope: Industry
Related coverage
More related coverage
Hyman, Phelps & McNamara (FDA Law)/3h ago
Coming Soon: Proposed Rule to Remove “Adequate Provision” (and Ban DTC TV Ads?)
Roche Newsroom/9h ago
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
Astellas Pharma/11h ago
China’s National Medical Products Administration Accepts Biologics License Application for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Muscle-Invasive Bladder Cancer
Natco Pharma/14h ago